How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

69 results for

"Cannabidiol"

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Cannabidiol (Epidioloex) - To treat rare, severe forms of epilepsy

Cannabidiol (Epidioloex) - To treat rare, severe forms of epilepsy Drug Approval Package: Epidiolex (Cannabidiol) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Epidiolex (Cannabidiol) Company: GW Research Ltd. Application Number: 210365 Orig 1 Approval Date: 07/27/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2017 FDA - Drug Approval Package

2. Epilepsy among Pediatric Patients: The Use of Cannabidiol and Potential Impacts on Quality of Life

Epilepsy among Pediatric Patients: The Use of Cannabidiol and Potential Impacts on Quality of Life "Epilepsy among Pediatric Patients: The Use of Cannabidiol and Potentia" by Mary E. Schuwerk < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Chronic epilepsy can cause severe impairments with respect to physical, mental, and social aspects of a child’s life leading (...) to low self-esteem, anxiety, depression, impaired memory and attention, lack of independence, and social stigma. Controlling seizures and their negative sequelae can be challenging in those with early onset epilepsy as they are often refractory to standard therapies. A further challenge is that all currently available anti-epileptic drugs have been shown to cause adverse cognitive effects and a certain degree of toxicity. However, cannabidiol (CBD), an agent found in cannabis, has been proven

2019 Pacific University EBM Capstone Project

3. Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults

Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed (...) technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults June 2017 A pharmaceutical formulation of the cannabis extract, cannabidiol is being developed for those patients who

2017 NIHR Innovation Observatory

4. Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines

Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness (...) and Guidelines Published on: May 4, 2016 Project Number: RB0983-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question 1. What is the clinical effectiveness of delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with Multiple Sclerosis? 2. What are the evidence-based guidelines associated with delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with Multiple Sclerosis? Key Message Three systematic

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®)

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) Penarth: All Wales (...) Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1814. 2014 Authors' conclusions Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) is recommended as an option for use within NHS Wales as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically

2015 Health Technology Assessment (HTA) Database.

6. Cannabidiol for epilepsy in adults: a systematic review

Cannabidiol for epilepsy in adults: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

7. Cannabidiol (CBD) for autism spectrum disorders: a systematic review

Cannabidiol (CBD) for autism spectrum disorders: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

8. The therapeutic effects of cannabidiol for the treatment of crack cocaine dependence: a systematic review

The therapeutic effects of cannabidiol for the treatment of crack cocaine dependence: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

9. Efficacy and safety of cannabidiol in the treatment of conflict-related post-traumatic syndrome disorder on humans compared to standard anti-stress drugs: a systematic review and meta-analysis protocol

Efficacy and safety of cannabidiol in the treatment of conflict-related post-traumatic syndrome disorder on humans compared to standard anti-stress drugs: a systematic review and meta-analysis protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

10. How does cannabidiol (CBD) influence the acute effects of delta-9- tetrahydrocannabinol (?9-THC) in humans? A systematic review

How does cannabidiol (CBD) influence the acute effects of delta-9- tetrahydrocannabinol (?9-THC) in humans? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

11. Changes in delta-9-tetrahydrocannabinol (?9-THC) and cannabidiol (CBD) in cannabis

Changes in delta-9-tetrahydrocannabinol (?9-THC) and cannabidiol (CBD) in cannabis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

12. A coordinate-based meta-analysis of neuroimaging studies investigating the acute effects of cannabidiol (CBD) on brain function

A coordinate-based meta-analysis of neuroimaging studies investigating the acute effects of cannabidiol (CBD) on brain function Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

13. Efficacy and safety of cannabidiol in the treatment of tumors in humans: a systematic review and meta analysis

Efficacy and safety of cannabidiol in the treatment of tumors in humans: a systematic review and meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

14. Cannabidiol as a treatment for mood disorders: a systematic review

Cannabidiol as a treatment for mood disorders: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2019 PROSPERO

15. Cannabidiol (CBD) in the treatment of infantile epilepsy: systematic review with metanalysis

Cannabidiol (CBD) in the treatment of infantile epilepsy: systematic review with metanalysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2018 PROSPERO

16. Neuroprotective role of cannabidiol: a systematic review

Neuroprotective role of cannabidiol: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2018 PROSPERO

17. Systematic review of cannabidiol for psychotic disorders

Systematic review of cannabidiol for psychotic disorders Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2018 PROSPERO

18. Cannabidiol and withdrawal treatment

Cannabidiol and withdrawal treatment Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email

2018 PROSPERO

19. Cannabidiol as a candidate alcohol use disorder pharmacotherapy: a systematic review

Cannabidiol as a candidate alcohol use disorder pharmacotherapy: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

20. Cannabidiol and emotional memory: a systematic review

Cannabidiol and emotional memory: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2018 PROSPERO